Company
Lung Cancer Cough (LCC) is a devastating problem and a significant opportunity
Bringing Relief Where It Matters Most
Biovara is pioneering a breakthrough treatment for one of the most distressing symptoms of advanced lung cancer—chronic, intractable cough.
Founded by an expert team with decades of experience in pharmaceutical innovation and clinical development, Biovara is built on validated science and credible leadership.
Our mission is simple yet powerful: to develop and deliver the first targeted, effective therapy for lung cancer cough—a condition that impacts quality of life but, until now, has lacked a viable treatment.
Lung Cancer Cough (LCC)
A devastating problem and a big opportunity
- Chronic cough is mentally and physically debilitating and distressing for patient and family; the most reported symptom of lung cancer.
- There is currently no effective treatment for LCC.
- Biovara’s ‘LipAprep product’ is designed for efficacy – based upon the evidence of physician led trials.
m
People are diagnosed with lung cancer each year.
>%
Late-stage lung cancer patients experience lung cancer cough.
Meet the Leadership Team
Dr. Simon Yaxley
Chief Executive Officer (CEO)
- Adviser, variety of drug development organisations.
- Founder, Premier Research. CRO specializing in oncology, CNS disorders and pain. Grew the business to 1,400+ drug development professionals across 26 countries. Sold to a private equity sponsor for £100m+.
- 30+ years of drug development experience.
- Neuroscience PhD,
Oxford University.
Ralph Browning
Chief Commercial Officer (CCO)
- Operating and investment partner, private and public companies in oncology drug sector enabled by exclusive rights to Oxford University biotech spinouts.
- Co-founded Deutsche Bank AG’s Islamic Finance subsidiary.
- SVP, MasterCard. Responsible for commercial development of their electronic cash product.
- Graduate of The London School of Economics.
George Style
Interim Chief Financial Officer (CFO)
- Partner, Cooper Parry working with business at all stages across different sectors.
- Experience includes advising IP intensive Oxford University spinouts.
- Professional advice includes coordinating the strategy and delivery of audit, tax and accountancy support to clients and individuals.
- Qualified with PWC.
Meet the Leadership Team
Dr. Simon Yaxley
Chief Executive Officer (CEO)
- Adviser, variety of drug development organisations.
- Founder, Premier Research. CRO specializing in oncology, CNS disorders and pain. Grew the business to 1,400+ drug development professionals across 26 countries. Sold to a private equity sponsor for £100m+.
- 30+ years of drug development experience.
- Neuroscience PhD, Oxford University.
Ralph Browning
Chief Commercial Officer (CCO)
- Operating and investment partner, private and public companies in oncology drug sector enabled by exclusive rights to Oxford University biotech spinouts.
- Co-founded Deutsche Bank AG’s Islamic Finance subsidiary.
- SVP, MasterCard. Responsible for commercial development of their electronic cash product.
- Graduate of The London School of Economics.
George Style
Interim Chief Financial Officer (CFO)
- Partner, Cooper Parry working with business at all stages across different sectors.
- Experience includes advising IP intensive Oxford University spinouts.
- Professional advice includes coordinating the strategy and delivery of audit, tax and accountancy support to clients and individuals.
- Qualified with PWC.
